Lusupultide

Drug Profile

Lusupultide

Alternative Names: BY 2001; Lung surfactant factor; Recombinant surfactant protein C; rSP-C

Latest Information Update: 02 Apr 2008

Price : $50

At a glance

  • Originator Scios
  • Developer Nycomed
  • Class Phospholipids; Pulmonary surfactants; Recombinant proteins; Surfactants
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adult respiratory distress syndrome
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Adult respiratory distress syndrome

Highest Development Phases

  • Discontinued Adult respiratory distress syndrome

Most Recent Events

  • 01 Jun 2007 Lusupultide received Fast Track designation for Adult respiratory distress syndrome [Intratracheal] in the US
  • 02 Sep 2004 A study has been added to the Respiratory Tract Disorders therapeutic trials section
  • 16 Jun 2004 Phase-III clinical trials in Adult respiratory distress syndrome in US (Intratracheal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top